VG Life Sciences, Inc. Reports Positive Results from First Stage of Ovarian Cancer Clinical Trial Using Sorafenib (Nexavar) Combined With Hydroxychloroquine

SAN MARINO, Calif.--(BUSINESS WIRE)--VG Life Sciences (OTC Pink: VGLS) reports details of the successful completion of the first stage of its Phase I Trial to treat ovarian cancer. The study examines the safety and efficacy of one of VG Life Sciences’ MDT compounds, hydroxychloroquine (HCQ), in combination with an existing cancer drug, sorafenib (marketed as Nexavar™), which was co-developed by Bayer AG and Onyx Pharmaceuticals.